More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...
Shortages and the sky-high cost of the new weight loss drugs has led to an explosion of compounded alternatives sold online, through telehealth sites and in compounding pharmacies. Unfortunately, most ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Stocktwits on MSN23h
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts DividedHims & Hers Health, Inc. shares surged 17.5% on Wednesday, marking their best performance in a week and hitting fresh highs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback